Stock Groups

French court backs class action against Sanofi over Depakine drug

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – The Sanofi logo is seen in Vitry-sur-Seine (France), August 6, 2019 REUTERS/Charles Platiau

PARIS, (Reuters) – A French court ruled Wednesday that Depakine’s victims could form a class against the drugmaker. The epilepsy drug caused learning and birth defects when it was administered to pregnant women. Sanofi France Info radio reported France Info (NASDAQ:), citing news agency AFP.

Victims’ association APESAC (which represents 7,500 families) launched the class-action in September 2021 against Sanofi. It was put under formal investigation for manslaughter in relation to Depakine in 2020.

Sanofi at the time denied the allegations and stated that it would contest the validity of the investigation.

Tribunal Judiciaire de Paris did not respond immediately to our requests.

Sanofi did not respond to our request for comment. At 1035 GMT, its shares rose 0.6% to 88.67, which was 0.5% higher than the benchmark in France.

According to French authorities, Depakine is responsible for neurodevelopmental and deformities in as many as 30,400 children.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]